Subscribe To
Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
Data reinforce brilaroxazine’s differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion profiles of brilaroxazine were similar across mice, canines, and humans CUPERTINO, Calif., May 22, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company […] The post Reviva Pharmaceuticals Announces Presentatio...
Read More
Content Topics
Reviva
Pharmaceuticals
Announces
Presentation
Clinical
Pharmacology
Studies
Brilaroxazine
Annual
Meeting
Forex
Posted: May 22 2023, 10:30
Author Name: forextv
Views: 081569